Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.63 |
| ▸ | XDH | P47989 | 2/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407603 | 0.83 | GDA (0.63) | GDAXDHPOLA1PNP | |
| SCHEMBL2051369 | 0.83 | GDA (0.63) | GDAXDHPOLA1PNP | |
| SCHEMBL22885 | 0.83 | GDA (0.68) | GDAXDHPOLA1PNP | |
| SCHEMBL2983854 | 0.83 | GDA (0.68) | GDAXDHPOLA1PNP | |
| SCHEMBL8886042 | 0.83 | GDA (0.63) | GDAXDHPOLA1PNP | |
| SCHEMBL852109 | 0.83 | GDA (0.63) | GDAXDHPOLA1PNP | |
| SCHEMBL41789 | 0.83 | GDA (0.63) | GDAXDHPOLA1PNP | |
| SCHEMBL1843779 | 0.83 | GDA (0.63) | GDAXDHPOLA1PNP | |
| SCHEMBL9960821 | 0.81 | XDH (0.69) | GDAXDHPOLA1PNP | |
| SCHEMBL5935074 | 0.81 | XDH (0.78) | GDAXDHPOLA1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630867-B2 | Devices for CRISPR effector system based diagnostics | THE BROAD INSTITUTE, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250243471-A1 | PROGRAMMABLE PATTERN RECOGNITION COMPOSITIONS | BROAD INST INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250129355-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH | 2025-04-24 | — | — | US | disclosed |
| US-20250075268-A1 | CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-03-06 | — | — | US | disclosed |
| US-12203145-B2 | CRISPR effector system based diagnostics for virus detection | THE BROAD INSTITUTE, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4119663-B1 | CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS | BROAD INST INC (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-111448311-B | Diagnostic system based on multiple effector CRISPR | 博德研究所 | 2024-11-19 | — | — | CN | disclosed |
| CN-111108220-B | Diagnostic based on CRISPR effect system for virus detection | 博德研究所 | 2024-11-19 | — | — | CN | disclosed |
| US-20240352454-A1 | MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-10-24 | — | — | US | disclosed |
| EP-1546164-A1 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG Life Sciences Ltd. (KR) | 2005-06-29 | — | — | EP | disclosed |
| US-20040127454-A1 | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases | RESPROTECT GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
| WO-2004029064-A1 | (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF | LG LIFE SCIENCES LTD. (KR) | 2004-04-08 | — | — | WO | disclosed |
| EP-1334109-A2 | IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES | Santaris Pharma A/S (DK) | 2003-08-13 | — | — | EP | disclosed |
| US-20020086998-A1 | Synthesis of purine locked nucleic acid analogues | SANTARIS PHARMA A/S (DK) | 2002-07-04 | — | — | US | disclosed |
| WO-2002028875-A2 | IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES | CUREON A/S (DK) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002024323-A2 | HIGH DENSITY MOLECULAR ARRAYS ON POROUS SURFACES | PICOLITER INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0824536-B1 | ANTIMALARIAL ORGANOMETALLIC IRON COMPLEXES | UNIV LILLE SCIENCES TECH (FR) | 2001-08-22 | — | — | EP | disclosed |
| EP-0338168-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| US-4508898-A | Antiviral triazine compounds | SYNTEX (U.S.A.) INC. | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086998-A1 | Synthesis of purine locked nucleic acid analogues | RNGTT, PNP, UNG | GDA 77/4885XDH 598/4885POLA1 757/4885 |
| US-20040127454-A1 | Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases | PNP, TYMP, ENTPD5 | GDA 17/4885XDH 219/4885POLA1 684/4885 |
| US-12630867-B2 | Devices for CRISPR effector system based diagnostics | ZFR, MTREX, ADAR | GDA 1128/4885XDH 2266/4885POLA1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.